HER2阳性的乳腺癌
1German Breast Group, c/o GB Forschungs GmbH, Neu-Isenburg, Germany.
Lancet (London, England)
|December 13, 2016
概括
抗HER2疗法改变了HER2阳性乳腺癌的治疗方法,改善了生存率和病理完整反应率. 由于这种疾病的持续死亡率,继续进行研究至关重要.
科学领域:
- 癌症学
- 医学研究
背景情况:
- HER2阳性乳腺癌是一个重大的临床挑战.
- 抗HER2疗法已经彻底改变了治疗模式.
研究的目的:
- 审查转移性和早期HER2阳性乳腺癌治疗的关键进展.
- 突出抗HER2疗法对患者结果的影响.
主要方法:
- 对HER2阳性乳腺癌的临床数据和治疗结果的审查.
- 新辅助和辅助疗法研究的分析.
主要成果:
- 在新辅助疗法中,珀图苏玛和特拉斯图苏玛的病理完整反应率较高.
- 在组合治疗中观察到无事件生存率的改善.
- 转移性HER2阳性乳腺癌的存活率接近5年.
结论:
- 抗HER2治疗显著改善了HER2阳性乳腺癌的预后.
- 尽管有进展,但对新疗法的持续研究对于降低死亡率至关重要.
相关概念视频
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:38Mitogens and the Cell Cycle
8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K